Clinical Trial Search

Primary: Proportion of Participants With Recorded Blood Pressure Values in Office — 43; 44; 49; 56 Participants

Primary: Number of Participants Whose Blood Pressure Was Assessed in the First Ten Days Following Discharge — 45; 95 Participants

Primary: Percent of Participants Eligible, Enrolled and Retained (Feasibility) — 61 Participants

Primary: Number of Participants With Persistent Postpartum Hypertension Defined as Systolic Blood Pressure ≥ 150 and/or Diastolic Blood Pressure ≥ 100 mmHg — 26; 34 Participants

Primary: Average Mean Arterial Blood Pressure- Mild Group — 93; 93 mmHg

Primary: Difference in Systolic Blood Pressure (SBP) — 131.8; 132.0; 129.1; 129.1 mmHg

Primary: Mean Arterial Blood Pressure (MAP) — 88.9; 86.8 mmHg

Primary: Length of Stay — 73.5; 72.0 hours

Primary: Time to Achieve Non Severe Range Blood Pressure — 10; 20 minutes

Primary: Persistently Elevated Blood Pressures 7 Days Postpartum — 10; 23 Participants — p=0.03

Primary: Adherence to the American College of Obstetricians and Gynecologists Guideline of Postpartum Blood Pressure Check Within 10 Days Postpartum — 59; 89 Participants…

Primary: Blood Pressure (BP) Surveillance Adherence — 0.0; 61.1 percentage of recommended BPs reported

Primary: Aim 1: Number of Participants Enrolled — 55 Participants

Primary: Duration of Severe-range Hypertension After Delivery — 38.0; 35.3 hours — p=0.3

Primary: Mean Systolic Blood Pressure During Hour After Study Drug — 147; 152 mmHg

Primary: Time (Hours) to Attain Sustained Blood Pressure Goal After Treatment Initiated With Antihypertensive Medication — 37.6; 38.2 hours

Primary: Mean Arterial Pressure — 93; 94 mm Hg — p=0.54

Primary: Median Number of Remote Blood Pressure (rBPM) Measurements Obtained Per Participant — 6 Number of rBPM measurements

Primary: Number of Participants With Stage 2 Hypertension — 8; 12 Participants

Primary: Number of Participants Attending a Comprehensive Postpartum Visit — 84; 89 Participants

Primary: Prolonged Hospitalization — 13; 17 Participants

Primary: Composite Adverse Perinatal Outcome — 353; 427; 272; 336 Participants — p=<0.001

Primary: Change From Baseline at End of Treatment Period (at 60 Hours) in Hamilton Rating Scale for Depression (HAM-D) Total Score — -8.75; -20.97 score on a scale — p=0.008

Primary: Eating Habits Confidence Survey — 4.2; 4.5 units on a scale

Primary: Positive Predictive Value of Earliest Available Platelet Count — 99; 90; 100 percentage of positive platelet counts

Primary: Number of Patients With Documented Counseling on Transitions of Care — 38; 28 Participants

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 4; 0 Participants

Primary: Microvascular Endothelial Function (Cutaneous Conductance, %Maximum) — 95; 77 % of maximal cutaneous conductance

Primary: Number of Participants With the Change in Blood Pressure (Both Systolic and Diastolic) Under the Treatment of NIfedipine 30mg XL Versus Placebo — 18; 27 Participants

Primary: Fibrinogen Level at 2 Hours After Delivery — 186; 418 mg/dL — p=<0.05